NRG raises $67 million for a small molecule aimed at Parkinson’s and ALS.
PRIVATESep 08, 2025
Amount Raised
$67 Million
Round Type
Funding Round
StevenageBiotechnologyHealth CareTherapeutics
Investors
Sv Health
Description
NRG has successfully raised $67 million to develop a small molecule targeting Parkinson's disease and ALS. The funding will support the advancement of their innovative treatments. This investment demonstrates confidence in NRG's groundbreaking research. The company aims to make significant strides in neurology with this funding.
Who to call at NRG Therapeutics, and when
A new round usually means NRG Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
An alert the day NRG Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at NRG Therapeutics, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
NRG Therapeutics
Location
Stevenage, England, United Kingdom
About
NRG Therapeutics is a neuroscience drug discovery company building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson's and Amyotrophic Lateral Sclerosis (ALS), also known as motor neurone disease (MND).
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment NRG Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
StevenageBiotechnologyHealth CareTherapeutics